Cognition Therapeutics, Inc.

1.91 USD
-0.13 (-6.37%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cognition Therapeutics, Inc. stock is down -27.1% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 June’s closed higher than May. 100% of analysts rate it a buy.

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease.

  • Chardan Capital
    Thu Jun 6, 16:31
  • HC Wainwright & Co.
    Wed May 29, 06:53